Johnson & Johnson (JNJ)
5 Dec 2016
ZURICH Actelion's silence speaks volumes to the dozens of event-driven hedge funds piling into the Swiss biotech firm, betting that Johnson & Johnson's (J&J) approach will result in an outright takeover and handsome returns.
A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.
ZURICH Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.
ZURICH/LONDON Some Actelion shareholders would be attracted by a $27 billion bid for the Swiss biotech company from Johnson & Johnson, leaving Chief Executive Jean-Paul Clozel with some explaining to do if he turned down an offer around that level.
Nov 29 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:
LONDON U.S. healthcare company Johnson & Johnson has raised its offer for Actelion, a source told Reuters on Tuesday, stepping up pressure on the Swiss biotech firm to accept a takeover deal.
ZURICH Shares in Swiss biotech company Actelion plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a "complicated deal" to link with U.S. healthcare giant Johnson & Johnson .
ZURICH, Nov 29 Shares in Swiss biotech company Actelion plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a "complicated deal" to link with U.S. healthcare giant Johnson & Johnson.
Nov 29 The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
ZURICH Actelion Chief Executive Jean-Paul Clozel's desire to keep Europe's biggest biotech company independent after building it from scratch, means Johnson & Johnson will have to pay a steep premium if a takeover is to succeed.
|General Electric Company (GE.N)||$31.11||-0.23|
|Procter & Gamble Co (PG.N)||$82.99||+0.59|
|Pfizer Inc. (PFE.N)||$31.59||-0.04|
|Novartis AG (NOVN.S)||CHF69.50||+0.75|
|Merck & Co., Inc. (MRK.N)||$60.25||-0.88|
|Baxter International Inc (BAX.N)||$43.89||-0.12|
|Stryker Corporation (SYK.N)||$112.01||-0.07|
|Boston Scientific Corporation (BSX.N)||$20.71||+0.36|
|Zimmer Biomet Holdings Inc (ZBH.N)||$101.10||+0.90|